|
The generic Allopurinol is the bioequivalent to the registered
branded medicine Zyloprim developed and produced by the world
renowned pharmaceutical manufacturers named Prometheus Laboratories
Inc., of the United States. The medicine in tablets form Zyloprim–Allopurinol
has been granted approval by the Food and Drugs Administration–FDA
under abbreviated New Drug Application-aNDA. The drug has been
indicated in the treatment of the patients having signs and symptoms
of primary or secondary phase of gout disorders, treating the
patients having leukemia, lymphoma and malignancies and are
undergoing chemotherapy for cancer which causes increase of serum
and urinary uric acid levels, treating the patients having
persistent calcium oxalate calculi whose routine uric acid secretion
are increased.
The pharmacology and usage of Allopurinol – Zyloprim denotes that
the structural analog of the natural purine base hypoxanthine drug
is used for preventing gout and renal calculi occurring due to
either uric acid or calcium oxalate and for treating uric acid
nephropathy, hyperuricemia associated with primary or secondary gout
as well as certain solid malignancies or tumors. The mechanism of
this drug is that it reduces or lowers the enzyme xanthine oxidase,
preventing the adaptation of the oxypurine hypoxanthine and xanthine
to uric acid. The drug is also proved of helping the assimilation of
hypoxanthine and xanthine into DNA and RNA thereby helping further
reduction of serum uric acid concentrations. Based on the positive
findings of the clinical trials on the Allopurinol – Zyloprim drug
it is approved for manufacture, sale and distribute in the United
States in various dose strengths in tablet forms.
|
